AstraZeneca disputes IRA’s orphan drug provisions in latest legal challenge to the law
AstraZeneca is the latest pharma company to challenge the Inflation Reduction Act in court, this time zeroing in on the law’s provisions around orphan drugs.
The company filed a complaint Friday in US District Court for the District of Delaware, arguing that the drug price negotiation provisions in the IRA “run headlong” into the Orphan Drug Act, which was passed in 1983 and is intended to encourage companies to invest in treatments for rare diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.